{
  "docId": "019de514-6ff5-7310-813b-bef8d5f9ec91",
  "docSlug": "dbbeae38634aeeee4a36f290777f18f9",
  "documentTitle": "Vivani Medical | Mergers and Acquisitions Presentation Deck | 27 slides",
  "authorId": "vivani-medical",
  "authorName": "Vivani Medical",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 27,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a table to present a roadmap and bullet points to detail progress.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-6ff5-7310-813b-bef8d5f9ec91/20",
  "deckHref": "/decks/019de514-6ff5-7310-813b-bef8d5f9ec91",
  "deckJsonHref": "/decks/019de514-6ff5-7310-813b-bef8d5f9ec91.json",
  "deckAnchorHref": "/decks/019de514-6ff5-7310-813b-bef8d5f9ec91#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.76,
        "x": 0.12,
        "y": 0.78
      },
      "kind": "list",
      "text": "Progress towards IND-enabling activities: Development of both low dose and high dose versions of NPM-119 to be used in LIBERATE-1 is complete; Recent extensive studies have confirmed excellent biocompatibility of NPM-119's device constituent; NPM-119 was well tolerated in a preclinical GLP toxicology study; GMP production of LIBERATE-1 clinical supplies is underway",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9ec928d-1888-4d04-a5a2-fbfc6a0d5677",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.76,
        "x": 0.12,
        "y": 0.64
      },
      "kind": "paragraph",
      "text": "We expect to utilize the 505(b)(2) pathway, which permits submissions to rely, in part, on the safety and effectiveness of a previously approved product, which may potentially result in a more expeditious pathway to FDA approval.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93cb679a-de15-4760-9aee-320e3d376a72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.76,
        "x": 0.12,
        "y": 0.24
      },
      "kind": "table",
      "text": "Year(s) | Milestone | Status; 2020 | FDA Pre-IND Meeting | Completed; 4Q2022 / 1Q2023 | File IND to support Ph 2 (LIBERATE-1) clinical study | On-Track; 2023 | Deliver LIBERATE-1 top-line results | Projected",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1565f82b-df80-4f64-9c4b-d5caea08a937",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.76,
        "x": 0.12,
        "y": 0.06
      },
      "kind": "title",
      "text": "NPM-119 Clinical + Regulatory Development Near-Term Plan",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e6fc185d-2c19-408b-924c-0992252df101",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}